Press release of the 2019 European Society of Cardiology Congress
References
1. Solomon S.D., McMurray J.J.V., Anand I.S. et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. The New England journal of medicine. 2019. DOI: 10.1056/NEJMoa1908655.
2. Bhatt D., Steg P.G. THEMIS and THEMIS-PCI: New Option for Antiplatelet Therapy in Patients with Stable Atherosclerosis and Diabetes: Key Findings from THEMIS and THEMIS-PCI. European heart journal. 2019: ehz707. https://doi.org/10.1093/eurheartj/ehz707.
3. Bhatt D.L., Steg P.G., Mehta S.R. et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394(10204):1169–1180. DOI: 10.1016/s0140–6736 (19) 31887–2.
4. Steg P.G., Bhatt D.L., Simon T. et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. New England journal of medicine. 2019;381(14):1309–1320. DOI: 10.1056/NEJMoa1908077.
5. Solomon S.D., Rizkala A.R., Gong J. et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction Rationale and Design of the PARAGON-HF Trial. Jacc-Heart Failure. 2017;5(7):471–82. DOI: 10.1016/j.jchf.2017.04.013.
6. Knuuti J., Wijns W., Saraste A. et al. Eur Heart J. 2019: pii: ehz425. DOI: 10.1093/eurheartj/ehz425. [Epub ahead of print].
7. Wang J., He S.-Y. Effect of ramipril on progression of nonculprit lesions in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. J Geriatr Cardiol. 2019;16:695–700.
8. McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England journal of medicine. 2019. DOI: 10.1056/NEJMoa1911303.
9. McMurray J.J.V., DeMets D.L., Inzucchi S.E. et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). European journal of heart failure. 2019;21(5):665–675. DOI: 10.1002/ejhf.1432.
2. Bhatt D., Steg P.G. THEMIS and THEMIS-PCI: New Option for Antiplatelet Therapy in Patients with Stable Atherosclerosis and Diabetes: Key Findings from THEMIS and THEMIS-PCI. European heart journal. 2019: ehz707. https://doi.org/10.1093/eurheartj/ehz707.
3. Bhatt D.L., Steg P.G., Mehta S.R. et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394(10204):1169–1180. DOI: 10.1016/s0140–6736 (19) 31887–2.
4. Steg P.G., Bhatt D.L., Simon T. et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. New England journal of medicine. 2019;381(14):1309–1320. DOI: 10.1056/NEJMoa1908077.
5. Solomon S.D., Rizkala A.R., Gong J. et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction Rationale and Design of the PARAGON-HF Trial. Jacc-Heart Failure. 2017;5(7):471–82. DOI: 10.1016/j.jchf.2017.04.013.
6. Knuuti J., Wijns W., Saraste A. et al. Eur Heart J. 2019: pii: ehz425. DOI: 10.1093/eurheartj/ehz425. [Epub ahead of print].
7. Wang J., He S.-Y. Effect of ramipril on progression of nonculprit lesions in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. J Geriatr Cardiol. 2019;16:695–700.
8. McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England journal of medicine. 2019. DOI: 10.1056/NEJMoa1911303.
9. McMurray J.J.V., DeMets D.L., Inzucchi S.E. et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). European journal of heart failure. 2019;21(5):665–675. DOI: 10.1002/ejhf.1432.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
